Equities analysts predict that CymaBay Therapeutics Inc (NASDAQ:CBAY) will post earnings of ($0.38) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.45). CymaBay Therapeutics posted earnings per share of ($0.32) during the same quarter last year, which suggests a negative year over year growth rate of 18.8%. The business is scheduled to report its next earnings report on Thursday, February 27th.
On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($1.49) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.42). For the next year, analysts expect that the business will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.59) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01).
In related news, CEO Sujal Shah bought 5,000 shares of CymaBay Therapeutics stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the chief executive officer now owns 111,900 shares in the company, valued at $618,807. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 11,900 shares of company stock worth $59,600. Company insiders own 4.20% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CBAY. Bank of Montreal Can lifted its holdings in shares of CymaBay Therapeutics by 1,372.0% in the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,311 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of CymaBay Therapeutics during the second quarter worth $80,000. Tower Research Capital LLC TRC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $61,000. Aperio Group LLC acquired a new position in shares of CymaBay Therapeutics during the second quarter worth $104,000. Finally, SG Americas Securities LLC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $85,000. Hedge funds and other institutional investors own 96.46% of the company’s stock.
CBAY stock traded up $0.17 during midday trading on Tuesday, reaching $1.89. 75,051 shares of the company’s stock traded hands, compared to its average volume of 3,930,757. The company has a market capitalization of $116.79 million, a P/E ratio of -1.51 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.12 and a quick ratio of 13.12. CymaBay Therapeutics has a fifty-two week low of $1.29 and a fifty-two week high of $14.00. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $5.96.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.